Drug Trial Radar · NCT06806657
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Apr 28, 2025
Primary completion
Jun 29, 2026
Study completion Jun 29, 2026
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Feb 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
Conditions
- Hereditary Angioedema
Interventions
GaradacimabBiological
Participants will receive a loading dose of garadacimab, followed by once monthly garadacimab administration for 2 months. Garadacimab will be given as a subcutaneous injection. The timing for the administration of the loading dose (first administration of garadacimab) is determined by the dosing schedule of the current HAE prophylactic treatment. No washout necessary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 95 (End of study [EoS])
- Percentage of Participants With TEAEsTime frame: Up to Day 95 (EoS)
- Number of TEAEsTime frame: Up to Day 95 (EoS)
- Rate of TEAEs per injectionTime frame: Up to Day 95 (EoS)
- Rate of TEAEs per participant yearTime frame: Up to Day 95 (EoS)
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Research Solutions of Arizona
Litchfield Park, Arizona
Allergy and Asthma Clinic of Northwest Arkansas
Bentonville, Arkansas
Donald Levy M.D.
Orange, California
Raffi Tachdjian MD, Inc.
Santa Monica, California
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Chronicle Bio
West Valley City, Utah
Clinique Spécialisée en Allergie de la Capitale
Québec, Canada
McMaster University-Hamilton
Hamilton, Ontario, Canada
Montreal Clinical Research Institute
Montreal, Quebec, Canada
HZRM Hämophilie Zentrum Rhein Main GmbH
Frankfurt, Germany
Hautklinik und Poliklinik der Universitätsklinik Mainz
Mainz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.